Seal Rock Therapeutics

Seal Rock Therapeutics is a clinical-stage company developing first-in-class treatments for inflammatory and fibrotic diseases with no available therapies. Our discovery and development efforts focus on small molecule inhibitors of ASK1 (Apoptosis Signal-Regulating Kinase 1), a protein that, when activated under various stress-related disease conditions, leads to severe pathological outcomes, including fibrosis and inflammation. The company’s lead clinical indication is non-alcoholic steatohepatitis (NASH), while its expanding R&D pipeline offers additional compelling opportunities for diseases with high unmet needs, including alcoholic hepatitis (AH), chronic kidney disease, heart failure, and Parkinson’s disease.